Trial Profile
Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 22 May 2014 New trial record